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Abstract
Expression and transport activity of Sodium-dependent Vitamin C Transporter 2 (SVCT2) was shown in various tissues and
organs. Vitamin C was shown to be cerebroprotective in several animal models of stroke. Data on expression, localization
and transport activity of SVCT2 after cerebral ischemia, however, has been scarce so far. Thus, we studied the expression of
SVCT2 after middle cerebral artery occlusion (MCAO) in mice by immunohistochemistry. We found an upregulation of SVCT2
after stroke. Co-stainings with Occludin, Von-Willebrand Factor and CD34 demonstrated localization of SVCT2 in brain
capillary endothelial cells in the ischemic area after stroke. Time-course analyses of SVCT2 expression by
immunohistochemistry and western blots showed upregulation in the subacute phase of 2–5 days. Radioactive uptake
assays using
14C-labelled ascorbic acid showed a significant increase of ascorbic acid uptake into the brain after stroke.
Taken together, these results provide evidence for the expression and transport activity of SVCT2 in brain capillary
endothelial cells after transient ischemia in mice. These results may lead to the development of novel neuroprotective
strategies in stroke therapy.
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Introduction
Ischemic stroke caused by cerebral artery occlusion results in
the activation of a complex cascade of pathophysiologic events,
including brain edema, blood-brain barrier disruption, oxidative
stress and neuroinflammation [1]. These events crucially deter-
mine the extent of the final infarction [2]. Therapeutic
interventions are remarkably limited and the number of patients
afflicted with cerebral ischemia is steadily increasing. In spite of
beneficial effects of thrombolysis, only a small percentage of acute
stroke patients qualifies for this specific therapy [3]. Despite
extensive experimental and clinical research, efforts to establish
neuroprotective therapies in stroke patients have not been
successful so far [4].
Ascorbic acid – also known as Vitamin C – has shown
neuroprotective effects in neuronal cell cultures [5,6,7] and animal
models of Alzheimer, Parkinson and Huntington disease [8,9,10].
In a mouse stroke model using middle cerebral artery occlusion
(MCAO), Vitamin C has been shown to be cerebroprotective
[11,12]. Despite its promising role in neuroprotection, the
transport pathway of Vitamin C into the brain is not entirely
clear. Two studies have shown transport of Vitamin C across the
blood-brain barrier in its oxidized form – dehydroascorbate – via
Glucose Transporters (GLUT) [5,13]. This has also been
demonstrated for the blood-retinal barrier [14]. However, it is
still debated whether this transport pathway is the physiological
mechanism of Vitamin C transport into the brain [15]. Another
possible pathway is transport of the reduced form of Vitamin C –
ascorbic acid – via Sodium-dependent Vitamin C Transporters
(SVCTs). In contrast to GLUTs, SVCTs are specific for Vitamin
C and transport ascorbic acid by an active, sodium-dependent
mechanism. Two types of SVCT have recently been cloned and
characterized: SVCT1 and 2. SVCT1 is expressed mainly in
tissues involved in whole-body homeostasis of Vitamin C like the
kidney, liver and gastrointestinal tract. SVCT2 on the other hand
is expressed predominantly in organs and tissues that functionally
require ascorbic acid like the neuroendocrine organs, the lung, the
peripheral and central nervous system [16,17,18]. In the brain,
expression of SVCT2 has been shown in hypothalamic glial cells
and neurogenic zones of the rat fetal brain [19,20]. SVCT2
mRNA transcripts have been detected by fluorescence in situ
hybridization after experimental cerebral ischemia in mice [21].
However, there were no studies so far on the expression of SVCT2
protein and transport activity of SVCT2 after stroke.
In this study, we analysed the expression, localization and
activity of SVCT2 in mouse brain after middle cerebral artery
occlusion (MCAO). We found expression of SVCT2 in brain
capillary endothelial cells after MCAO in mice. Upregulation of
SVCT2 occured in the subacute phase (2–5 days) after stroke.
Furthermore, we show transport of radioactively-labelled ascorbic
acid across the blood-brain barrier after MCAO in mice. Thus, we
show for the first time expression and transport activity of SVCT2
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17139in the blood-brain-barrier after transient ischemia in mice. These
results could be of importance for the development of antiox-
idative therapies of ischemic stroke.
Materials and Methods
Ethics statement
All animal experiments were done in strict accordance with a
protocol approved by the University of Muenster and the
government of North-Rhine-Westphalia (Landesamt fu ¨r Natur,
Umwelt und Verbraucherschutz Nordrhein-Westfalen, AZ 87-
51.04.2010.A273).
Animal stroke model
Adult male mice (Jackson Laboratories) weighing 20–30 g were
used in this study. Mice were allowed free access to water and food
before surgery. Anesthesia was induced with 2% and maintained
with 1% isoflurane in a mixture of 70% nitrous oxide and 30%
oxygen. A modified standard intraluminal filament technique was
used to induce transient focal cerebral ischemia [22,23]. The left
middle cerebral artery occlusion (MCAO) was induced by a 8-0
nylon monofilament (Ethilon; Ethicon, Norderstedt, Germany)
and coated with silicon resin (Xantopren; Heraeus, Dormagen,
Germany). Cerebral blood flow was continuously monitored using
a laser Doppler probe (Periflux 5001; Perimed, Stockholm,
Sweden) to verify ischemia and reperfusion. During the experi-
ment rectal temperatures were maintained at 37uC60,5uC with a
thermostat-controlled heating pad. After 30 min, the filament was
withdrawn to reperfuse the ischemic brain and the animals were
allowed to recover from anesthesia. After the appropriate survival
time, the animals were deeply anesthetized and perfused
transcardially with 4% paraformaldehyde (PFA). Brains were
rapidly removed from the skull, postfixed in 4% PFA (3 h),
immersed in 10% sucrose overnight, embedded in TissueTekH
(Sakura Finetek, Netherlands), frozen and stored at 280uC.
Immunohistochemistry
Immunhistochemistry was performed in MCAO mice on
10 mm-thick frozen coronal sections using SVCT2 rabbit poly-
clonal antibody (1:100, Santa Cruz) and an appropriate secondary
biotinylated goat anti rabbit antibody (1:100, Vectashield). Double
fluorescent staining was performed using SVCT2 in combination
with the Zonula occludens marker Occludin (1:100, Zymed
Laboratories), the neuronal marker NeuN (Chemicon), the glial
marker GFAP (Sigma), the endothelial marker Von-Willebrand-
Factor (1:50, Santa Cruz) and CD34 (1:100, BD Biosciences).
Immunostaining was visualized with a fluorescent microscope
(Leica DM microscop, Bensheim, Germany). Negative control
sections were used without the primary antibody. For quantifica-
tion, images were analysed with the software ImageJ (NIH).
Orthogonal sections of confocal microscopy stacks were computed
by the open source software BioImageXD (http://bioimagexd.
net).
Western blot
For western blot analysis, brains were dissected, the hemispheres
separated and frozen immediately at 280uC. Hemispheres were
incubated with lysis buffer (25 mM Tris, 1 mM NaVO3, 1% SDS
and 2 mM EDTA) on ice for 45 min. and then homogenized with
a Dounce homogenisator followed by multiple passes through a 21
gauge syringe. Lysates were then centrifuged at 4uC with 10,000
rgf for 15 min. Protein concentrations were determined by the
Bradford method. Samples with 10 mg of protein were loaded onto
10% SDS-polyacrylamide gels. After electrophoresis, proteins
were transferred to PVDF membranes (Millipore) in a wet blot
chamber (Biorad) at 4uC over night. Membranes were stained with
Ponceau Red (Biorad), de-stained with tris-buffered saline
containing 0.05% Tween (TBST), blocked with 4% milk powder
and incubated with primary antibodies SVCT2 (1:1000) or b-
Actin (1:10000) at 4uC over night. Membranes were washed with
TBST and incubated with HRP-conjugated secondary antibodies
(1:10000, Molecular Probes) at room temperature for one hour.
Bound antibodies were visualized using chemiluminescence
(Pierce) and x-ray films. Densitometric analysis of western blots
was performed with the program ImageJ (NIH).
Radioactive uptake assays
A solution of 2.5 mCi 14C-labelled L-ascorbic acid or
dehydroascorbate (160 mg/ml) and 5 mCi 3H-labelled inulin
(114 mg/ml) in 250 ml of 0,9% NaCl was injected into the tail
vein by standard procedures. 30 minutes after injection, animals
were sacrificed, brains quickly dissected, hemispheres separated
and kept on ice. Hemispheres were lysed with 300 ml buffer
containing 10 mM TrisHCl, 0.2% SDS and 2% Triton100. Brain
tissue was then homogenised using a Dounce homogenisator
followed by multiple passes through a 21-gauge syringe. Brain
homogenates were added to 2 ml of b-scintillation liquid (Roth). b-
radiation was then measured in a liquid scintillation counter (LKB
Wallac).
Data analysis
Data in text, tables, and figures are expressed as mean 6 SD.
Statistical comparisons among multiple groups were evaluated
using two-way analysis of variance followed by Tukey post-hoc test
for intergroup comparisons. For all statistical procedures,
differences were considered significant at P,0.05.
Results
SVCT2 is expressed in brain capillaries in infarcted brain
tissue after transient ischemia
To assess the expression of SVCT2 after middle cerebral artery
occlusion, brain sections of mice were immunohistochemically
stained with SVCT2 antibodies five days after MCAO. SVCT2
staining was visualized intensely in the infarct regions of ischemic
mice, whereas the hemispheres contralateral to the lesion showed
only weak immunoreactivity (Fig. 1, compare A to A’, D to D’, G
to G’). SVCT2 staining in infarcted brain tissue appeared in short,
linear, occasionally branched structures reminiscent of capillaries
(Fig. 1, arrows). To analyse the cellular localization of SVCT2
immunoreactivity, co-stainings with the endothelial tight junction
protein Occludin (Fig. 1A–C’), the neuronal marker NeuN
(Fig. 1D–F’) and the glial protein GFAP (Fig. 1G–I’) were
prepared. Co-localisation was found in co-stainings with Occludin
in the infarcted brain tissue, but not in the contralateral, non-
ischemic hemisphere (Fig. 1A–C’). SVCT2 was weakly expressed
in some NeuN positive cells of both hemispheres (Fig. 1D–F’,
arrowheads) as expected from a previous study showing SVCT2
expression by neurons of healthy rats [24]. GFAP-positive cells
showed no SVCT2 staining in either hemisphere (Fig. 1G–I’).
Untreated control mice showed no SVCT2 staining brain
endothelia in either hemisphere, consistent with previous reports
[20,24] (data not shown).
Occludin immunoreactivity is found in endothelial cells in tight
junctions and in the cytoplasm. However, it is not specific for
endothelial cells but is also found in epithelial tight junctions.
Thus, we used antibodies against Von-Willebrand Factor (VWF)
and CD34 to confirm endothelial localization of SVCT2 after
Sodium-Dependent Vitamin C Transporter in Stroke
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e17139Figure 1. SVCT2 is upregulated after stroke and mainly localized in endothelial structures. Sections of brain tissue from mice with MCAO
were stained with SVCT2 (red, left column) and co-stained with occludin (B, B’), NeuN (E, E’), GFAP (H, H’). Intense SVCT2- immunoreactivity was found
in the infarct area (ipsilateral), compared to only weak expression on the contralateral side (compare A to A’, D to D’, G to G’). Co-
immunohistochemistry with occludin showed colocalisation in linear, occasionally branched structures reminiscent of capillaries (A–C, D–F, G–I,
arrows). Co-stainings with NeuN showed weak SVCT2-immunoreactivity in NeuN positive cells in both hemispheres (D–F, D’–F’, arrowheads). Co-
stainings with GFAP showed no SVCT2-immunoreactivity in GFAP-positive cells (G–I, G’–I’). Size bars: 10 mm.
doi:10.1371/journal.pone.0017139.g001
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and VWF (Fig. 2A–C) as well as SVCT2 and CD34 (Fig. 2D–F) in
brain capillary endothelial cells in the infarcted area. In order to
demonstrate co-localisation of SVCT2 and VWF specifically,
double-immunolabeled sections were viewed with a confocal
microscope. Confocal microscopy also showed co-localisation of
SVCT2 and VWF in brain capillary endothelial cells in infarcted
brain tissue (Fig. S1A–C). Three-dimensional analysis of confocal
images confirmed colocalization in computed transverse sections
(Fig. S1C).
Taken together, these data provide evidence for the expression
of SVCT2 in brain capillary endothelial cells after MCAO in
mice.
Time-course of SVCT2 expression after MCAO
Pathological mechanisms after stroke occur in several phases
characterized for example by excitotoxicity in the early phase,
followed by inflammatory processes and apoptosis in later phases.
We were interested in the time course of SVCT2 expression after
MCAO to find out in which phase after stroke SVCT2
upregulation occurs.
We studied SVCT2 expression by immunolabeling of sections
from stroke mice at day 0, 2 and day 5 after MCAO. SVCT2
levels started to increase in the stroke area at day 2 and reached a
peak at day 5 (Fig. 3B). On the contralateral side no increase in
SVCT2 expression could be seen (Fig. 3B’). Quantification of
immunohistochemistry showed a slight increase of SVCT2
immunoreactivity at day 1, further increasing at day 2, reaching
significance at day 4, peaking at day 5 and declining again at day 7
(Fig. 3C).
To assess the time-course of SVCT2 expression after MCAO on
a whole protein level, we performed western blots of lysates from
the ipsi- and contralateral hemispheres of operated animals at 0, 2
and 5 days after MCAO and untreated control animals. Western
blot analysis showed that SVCT2 was upregulated in the infarcted
hemisphere after stroke, whereas no increase could be observed in
the contralateral hemisphere or in untreated control brains
(Fig. 4A). Quantification of western blot signals, normalized by
actin signals, showed that SVCT2 levels were not increased at day
0 (1 hour) after stroke; a slight increase could be observed at day 2
and a further increase at day 5 after stroke (Fig. 4B). Therefore,
western blot analysis confirmed the results of the immunohisto-
chemical studies.
These data show that SVCT2 expression is upregulated in the
subacute phase at days 2–5 after murine stroke.
Uptake of 14C-labelled ascorbic acid into brain tissue
after MCAO
After analysing the localization and time-course of SVCT2
expression after transient ischemia, we were interested if SVCT2
was functionally active in the blood-brain-barrier after stroke as
well. In order to test this, mice at day 0 and 5 after stroke as well as
control mice without stroke were injected with radioactively- (14C-)
labelled L-ascorbic acid. Since dehydroascorbate is known to be
transported across the blood-brain-barrier via GLUT both in
healthy mice and after stroke [25,26,27] - 14C-labelled dehydroas-
corbate was used as a positive control. 3H-labelled inulin was used
as a negative control because inulin does not permeate the intact
blood-brain-barrier.
Analysis of radioactive uptake showed that there was no
increase in ascorbic acid uptake into brain tissue of the infarcted
hemisphere at the time point of day 0, but a significant increase at
day 5 after stroke (Fig. 5). This finding is in line with the time-
course of SVCT2 expression in our immunohistochemical and
western blot analyses (see above). 14C-dehydroascorbate was
readily transported into brain tissue at all time points (Fig. 5), as
expected from previous reports [11,13]. Dehydroascorbate is
rapidly reduced to ascorbic acid intracellularly [28]. Thus, the
radioactivity measured in brain after 14C-dehydroascorbate
injection may actually come from 14C-dehydroascorbate that
was already reduced intracellularly to 14C-ascorbic acid. None-
theless, since reduction does not take place in the blood
circulation, radioactivity after 14C-dehydroascorbate injection
reflects Vitamin C transported into the brain as dehydroascorbate
not as ascorbic acid.
Figure 2. SVCT2 is localized in brain capillary endothelial cells after murine stroke. Brain sections of mice with focal cerebral ischemia
were stained with SVCT2 and Von-Willebrand factor (vWF) antibodies (A–C) or SVCT2 and CD34 antibodies (D–F). SVCT2 colocalised with both vWF
and CD34, indicating a localization in brain capillary endothelial cells. Size bars: 10 mm.
doi:10.1371/journal.pone.0017139.g002
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towards an increase after stroke, indicating a possible slight
perturbation of the blood-brain-barrier by the ischemic event.
However, the differences in 3H-inulin uptake levels were
insignificant and considerably smaller than those in 14C-ascorbic
acid uptake. There was no difference in 3H-inulin uptake between
day 0 and day 5 after stroke (Fig. 5). Therefore, the increased
uptake of 14C-ascorbic acid 5 days after stroke cannot be
explained by a destruction of the blood-brain-barrier.
Taken together, these data provide evidence for functional
activity of SVCT2 transporters in vivo leading to active transport
of ascorbic acid across the blood-brain barrier after stroke in mice.
Discussion
In this study we provide evidence, for the first time, for an
upregulation of SVCT2 protein expression after experimental
stroke in mice. After stroke, SVCT2 was localized specifically in
brain capillary endothelial cells immunoreactive for the tight
junction marker Occludin and the endothelial cell markers VWF
and CD34. The contralateral, non-ischemic hemisphere showed no
immunoreactivity for SVCT2 in endothelial cells. Apart from
endothelial cells, SVCT2 was weakly positive in neurons of both
hemispheres, but not in astrocytes. The time-course of SVCT2
expression in immunohistochemistry and immunoblotting showed
that SVCT2 was upregulatedin the subacute phase at day2–7, with
a peak at day 5 after transient ischemia. Furthermore, we found a
significant increase of L-ascorbic acid uptake into the brain at day 5
after MCAO, suggesting functional activity of SVCT2 in ascorbic
acid transport across the blood-brain-barrier after stroke.
Our radioactive uptake studies showed transport of labelled
dehydroascorbate as well as ascorbic acid into the brain after
stroke. Dehydroascorbate was transported into the brain without
stroke, in the acute phase and in the subacute phase after stroke,
while ascorbic acid was significantly transported across the blood-
brain-barrier only in the subacute phase after stroke. These data
match the expression courses of the respective transporters –
GLUT and SVCT2 – in brain capillary endothelia: GLUTs are
constitutively expressed in the brain endothelium in healthy as well
as ischemic brain tissue [25,26,27], whereas SVCT2, as we show
in our time course analyses, is expressed in brain endothelium only
in the subacute phase after stroke. As GLUTs are expressed in
control conditions and after stroke, transport of dehydroascorbate
into the brain could be found with and without stroke in our
present study and previous studies by other investigators [11,13]. It
is unclear, however, if this dehydroascorbate transport plays a
physiological role. Under physiological conditions, dehydroascor-
bate is found in blood only in small amounts compared to ascorbic
acid [29,30]. Since GLUTs are glucose transporters, dehydroas-
corbate competes with glucose for transport via GLUTs [31,32].
Thus, at physiological glucose and dehydroascorbate concentra-
tions, little transport of dehydroascorbate via GLUTs is to be
expected [15]. Overall, the mechanism of Vitamin C uptake into
the brain under physiological conditions is still under debate. It has
been suggested that Vitamin C enters the brain through the
choroid plexus and the cerebrospinal fluid [33]. Cultured choroid
plexus epithelial cells show a sodium-dependent Vitamin C
transport pathway and expression of SVCT2 [34]. Under
physiological conditions, no expression of SVCT2 in brain
capillary endothelial cells was detected in a study by Qiao et al.
[35], though SVCT2-expression developped during the process of
cell culturing – possibly attributable to oxidative stress. One study,
on the other hand, showed transport of radioactively labelled
ascorbic acid in isolated brain capillaries [36]. This study,
however, provided no data on SVCT2 expression on the RNA
or protein level. Our study presented here demonstrates expression
of SVCT2 and transport of ascorbic acid in brain capillary
endothelial cells only after stroke, not under physiological
conditions. This supports the hypothesis that under physiological
conditions ascorbic acid is transported via the choroid plexus but
after stroke – and possibly in other pathological conditions – there
Figure 3. Time-course of SVCT2 immunohistochemistry after
murine stroke. Brains of mice with a focal cerebral ischemia were
dissected at day 0, 1, 2, 4, 5 and 7 after stroke and stained for SVCT2
(red) and nuclei (DAPI, blue). Ipsilateral (A–B) and contralateral (A’–B’)
hemispheres of day 1 and 5 are shown. An increase of SVCT2
immunoreactivity was found in the ipsilateral hemisphere at day 5
(B). Contralateral hemispheres (A’–B’) showed only weak background
staining. Quantification of immunohistochemistry showed a significant
increase at day 4, a peak at day 5 and a decline at day 7 (C). Size bar:
10 mm. (** p,0.01, n=4).
doi:10.1371/journal.pone.0017139.g003
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17139Figure 4. Time-course of SVCT2 protein levels after stroke. To assess the levels of SVCT2 on a whole-protein level, brains of stroke mice were
dissected and lysed at day 0, day 2 and day 5 after stroke and analysed by western blot. Western blots showed only very weak SVCT2 bands in
animals without stroke and on day 0 after stroke. An increase in SVCT2 bands can be seen in ipsilateral hemispheres 2 days after stroke and a further
increase 5 days after stroke (A). Actin was used as a marker for protein loading (A). SVCT2 and actin bands were measured using image analysis
software ImageJ (NIH). Intensities of SVCT2 bands were normalized by the corresponding actin band. Semi-quantitative analysis of western blot
signals showed a significant increase of SVCT2 at days 2 and 5 in ipsilateral hemispheres (B). (** p,0.01, *** p,0.001, n=3).
doi:10.1371/journal.pone.0017139.g004
Figure 5. Uptake of 14C-labelled ascorbic acid into the brain is increased 5 days after stroke. Animals with focal cerebral ischemia and
control animals without stroke were injected with 14C-labelled ascorbic acid or dehydroascorbate and 3H-labelled inulin. Radioactive uptake assays
showed a significantly increased ascorbic acid uptake 5 days after stroke compared to animals without stroke or at day 0 after stroke.
Dehydroascorbate was transported into the brain at similar rates before, at day 0 and day 5 after stroke. At day 5 ascorbic acid transport was not
significantly lower than dehydroascorbate. Inulin uptake, as a marker for blood-brain-barrier integrity showed an insignificant trend towards an
increase after stroke. (*** p,0.001, ns = non-significant, n=4).
doi:10.1371/journal.pone.0017139.g005
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barrier.
Since it is known that the blood-brain-barrier is disturbed after
stroke, it has to be considered that a loss of blood-brain-barrier
function may have caused the increase in ascorbic acid uptake
after stroke. However, inulin, which cannot cross the intact blood-
brain-barrier and, thus, is a marker of blood-brain-barrier
breakdown, was only slightly, insignificantly increased after stroke.
This indicates that the observed elevation of ascorbic acid uptake
after stroke was not attributable to a reduction of blood-brain-
barrier function.
Previous studies have demonstrated expression of SVCT2 in
different cell types of the central and peripheral nervous system in
vivo and in vitro. SVCT2 was shown to be expressed and
functionally active in tanycytes - hypothalamic glial cells [20],
brain stem stem cells, neuroblastoma cells, embryonic and adult
neurons of different subtypes in rats and mice [7,19,24,37]. The
SVCT2 knockout mouse shows a severe phenotype with lung
failure and brain hemorrhage leading to early postnatal death
[38]. Brain ascorbic acid content in embryonal SVCT2-deficient
mice was dramatically reduced [38]. In our previous studies, we
found expression and activity of SVCT2 in Schwann cells and
axons of peripheral nerves [39]. In one previous study, mRNA
transcripts of SVCT2 were found in glial and neuronal cells in rats
after stroke [21]. Our present study provides evidence for the first
time for expression and transport activity of SVCT2 in the blood-
brain barrier in vivo. SVCT2 shows a strict specificity for L-
ascorbic acid, as D-ascorbic acid, dehydroascorbate and several
other forms of Vitamin C are not transported [16]. In contrast to
humans, mice are able so synthesize L-ascorbic acid in the liver.
Whether Vitamin C is delivered nutritionally as in humans or by
the liver as in mice, the expression and activity of Vitamin C
transporters in functional end-organs may be the same. However,
caution should be exercised in translation of results on Vitamin C
metabolism from mice to humans.
The function of ascorbic acid in the central nervous system and
specifically after stroke, however, remains elusive. Some studies
have suggested a function of ascorbic acid in free radical
scavenging and prevention of oxidative damage in brain tissue
and endothelia [6,7,40,41]. Interestingly, a study by Qiao et al.
showed that SVCT2 was not expressed in brain capillary
endothelial cells in untreated mice in vivo, but developed in
cultured brain capillary endothelial cells, which the authors
attributed to oxidative stress during the course of cell culturing
[35]. After cerebral ischemia, oxidative stress is one of the factors
leading to cell death by oxidation of various cell stuctures
including membrane-lipids, proteins and DNA [42]. The vascular
endothelium is considered one of the major targets of oxidative
stress injury [42,43,44]. Thus, increased expression of SVCT2 in
brain endothelia after stroke may have a role in the response to
increased oxidative stress. This study used an ischemia-reperfusion
model to induce a stroke in mice. Previous studies suggested that
reperfusion was a major cause of oxidative stress after stroke [45].
Hence, reperfusion may be the actual trigger of SVCT2-
upregulation in our study. On the other hand, there is one study
on ischemia without reperfusion in cats, in which brain ascorbic
acid fell markedly over the course of 24 hours after stroke [46].
This ascorbic acid decrease could also be a stimulus for SVCT2-
upregulation after stroke. Since our model used ischemia-
reperfusion it is not possible to differentiate between the effects
of the initial ischemia and the subsequent reperfusion. Further
studies will be necessary to clarify this aspect.
Oxidative stress parameters are significantly increased from
6 hours to 7 days after stroke [42], so it is a pathogenetic factor
present at the time-point of 2–5 days after stroke, at which we
found SVCT2 upregulation. Apart from oxidative stress, inflam-
matory processes are prominent at this time-point. Macrophages
and neutrophiles show a maximum of brain infiltration 2–5 days,
T-cells around 3–4 days after stroke [47,48]. A function of
ascorbic acid in protection of macrophages from oxidants
generated by phagocytosis of cellular remains has been suggested
[49]. Therefore, ascorbic acid uptake into the brain may be
necessary for the function of inflammatory cells infiltrating the
brain after stroke.
A previous treatment study showed a neuroprotective effect of
dehydroascorbate but not ascorbic acid after stroke in mice [11].
In this study ascorbic acid and dehydroascorbate were adminis-
tered right before stroke, 15 minutes and 3 hours after stroke, i.e.
in the acute phase. Our data show that at these time points
SVCT2 is not expressed in brain capillary endothelial cells and
radioactively labelled ascorbic acid is not taken up into the brain
yet. Thus, the time points of ascorbic acid treatment in the study
by Huang et al. [11] may have been to early to show a beneficial
effect of ascorbic acid on stroke in mice. Another study, however,
did show a neuroprotective effect of ascorbic acid itself given right
before stroke in monkeys [50]. Furthermore, dehydroascorbate is
reduced to ascorbic acid intracellularly, possibly consuming
antioxidants like NADPH and glutathione in cells. This may in
turn have pro-oxidative effects. Hence, the question of dehy-
droascorbate versus ascorbic acid as a therapeutic approach to
stroke is still controversial. Treatment studies administering
ascorbic acid in the time window of SVCT2 expression from
day 2 to 7 after stroke may be promising.
In summary, this study provides evidence for expression and
function of SVCT2 in brain capillary endothelia after transient
murine stroke. Ascorbic acid transported into the brain after stroke
may have a role in oxidative stress protection or macrophage
function. Further studies are necessary to assess the function of
ascorbic acid after stroke and the mechanisms leading to SVCT2
upregulation. A treatment study administering ascorbic acid to
mice with cerebral ischemia in the time window of SVCT2
expression after stroke is warranted on the basis of our data. Such
studies may lead to the development of novel therapeutic strategies
against stroke with the opportunity of a delayed time window for
treatment initiation.
Supporting Information
Figure S1 Confirmation of endothelial localization of
SVCT2 by confocal microscopy. Sections stained with
SVCT2 and VWF antibodies were viewed and photographed
with a confocal microscope to confirm colocalization. SVCT2
staining (A), VWF staining (B), and the merged image (C) are
shown. Computed orthogonal sections are shown to the right and
bottom of the merged image (C). Colocalization of SVCT2 and
VWF is shown in confocal images and computed orthogonal
sections, confirming endothelial localization of SVCT2 after
cerebral ischemia. Size bar: 25 mm.
(TIF)
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